» Articles » PMID: 8765048

Threonine 80 on HLA-B27 Confers Protection Against Lysis by a Group of Natural Killer Clones

Overview
Journal Eur J Immunol
Date 1996 Aug 1
PMID 8765048
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Recognition of major histocompatibility complex (MHC) class I molecules on target cells by natural killer (NK) cells inhibits NK cell-mediated lysis. Although it is known that this inhibitory effect is regulated by MHC polymorphism, the precise structural determinants remain undefined. Based on the capacity of different HLA-C and HLA-B motifs specifically to inhibit cytotoxicity of some NK clones, three different NK cell specificities (NK1, NK2 and NK3) have been described. In this study, the recognition of HLA-B27 by NK clones has been analyzed using C1R cells transfected with different HLA-B27 subtypes as target cells. Cytotoxicity was inhibited by the HLA-B*2705, -B*2701 -B*2703, -B*2704 and -B*2706 alleles, but not by -B*2702. This subtype is distinguished from the other B27 subtypes by the presence of isoleucine instead of threonine at position 80. Direct involvement of this residue was assessed by showing that site-directed mutagenesis of Thr80 to Ile80 in HLA-B*2705 reverted the NK protective effect of HLA-B*2705. Based on these data, we suggest that Thr80 could act as a single residue conferring target cell protection from lysis by a group of NK clones, tentatively designated NK4.

Citing Articles

HLA-B*44 and the Bw4-80T motif are associated with poor outcome of relapse-preventive immunotherapy in acute myeloid leukemia.

Komic H, Hallner A, Hussein B, Badami C, Wohr A, Hellstrand K Cancer Immunol Immunother. 2023; 72(11):3559-3566.

PMID: 37597015 PMC: 10576699. DOI: 10.1007/s00262-023-03506-3.


Epistatic interactions between killer immunoglobulin-like receptors and human leukocyte antigen ligands are associated with ankylosing spondylitis.

Hanson A, Vukcevic D, Leslie S, Harris J, Le Cao K, Kenna T PLoS Genet. 2020; 16(8):e1008906.

PMID: 32804949 PMC: 7451988. DOI: 10.1371/journal.pgen.1008906.


Killer Cell Immunoglobulin-like Receptor Variants Are Associated with Protection from Symptoms Associated with More Severe Course in Parkinson Disease.

Anderson K, Augusto D, Dandekar R, Shams H, Zhao C, Yusufali T J Immunol. 2020; 205(5):1323-1330.

PMID: 32709660 PMC: 7484130. DOI: 10.4049/jimmunol.2000144.


HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.

Erbe A, Wang W, Reville P, Carmichael L, Kim K, Mendonca E Front Immunol. 2017; 8:675.

PMID: 28659916 PMC: 5466980. DOI: 10.3389/fimmu.2017.00675.


Killer cell immunoglobulin-like receptor 3DL1 polymorphism defines distinct hierarchies of HLA class I recognition.

Saunders P, Pymm P, Pietra G, Hughes V, Hitchen C, OConnor G J Exp Med. 2016; 213(5):791-807.

PMID: 27045007 PMC: 4854737. DOI: 10.1084/jem.20152023.